Skip to main content
Grafa
Health
EyePoint LUGANO misses endpoint despite 42% reduction
Image for illustrative purposes only. Not a real photo.

EyePoint LUGANO misses endpoint despite 42% reduction

Share
  • EyePoint said DURAVYU did not meet LUGANO’s primary BCVA endpoint in the full dataset, although an ad hoc analysis showed non-inferiority.
  • EyePoint shares were down about 70% at $4.43 in early Nasdaq trading following the results.
  • DURAVYU reduced treatment burden by 42%, while EyePoint expects the second Phase 3 LUCIA readout in Q4 2026.

EyePoint (NASDAQ:EYPT) said DURAVYU 2.7mg missed LUGANO’s primary BCVA endpoint against 2mg aflibercept in the full Phase 3 dataset.

An ad hoc analysis excluding nine of 211 DURAVYU patients with unrelated vision loss showed non-inferiority to aflibercept at nominal p=0.0096.

DURAVYU reduced treatment burden 42%, while 54% remained supplement-free and 79% required zero or one supplemental injection through Week 56.

EyePoint expects LUCIA results in Q4 2026 before a potential 1H 2027 NDA filing.

Following the announcement, EyePoint's share price was down 70% at $4.43.

EyePoint ended Q2 with $180 million in cash and investments, which the company expects will fund operations into Q4 2027.

The company has also fully enrolled its COMO and CAPRI Phase 3 DME trials, with topline results expected in Q4 2027.

Frequently asked questions